✦ LIBER ✦

Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

✍ Scribed by B Flouvat; S Decourt; P Aubert; L Potaux; M Domart; A Goupil; A Baglin

Book ID: 117942186
Publisher: John Wiley and Sons
Year: 1980
Tongue: English
Weight: 719 KB
Volume: 9
Category: Article
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.1980.tb01065.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of ciprofloxacin tablet

Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis

✍ E. Singlas; A. M. Taburet; I. Landru; H. Albin; J. Ph. Ryckelinck 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 607 KB

The pharmacokinetics of the new penicill

The pharmacokinetics of the new penicillins: amoxycillin and flucloxacillin, in patients with terminal renal failure undergoing haemodialysis

✍ S. Simonian; P. L. Oe; J. Verhoef 📂 Article 📅 1973 🏛 Springer Netherlands 🌐 English ⚖ 48 KB

Pharmacokinetics of atenolol in patients

Pharmacokinetics of atenolol in patients with renal impairment

✍ J. Sassard; N. Pozet; J. McAinsh; J. Legheand; P. Zech 📂 Article 📅 1977 🏛 Springer 🌐 English ⚖ 660 KB

Citalopram pharmacokinetics in patients

Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis

✍ Olav Spigset; Staffan Hägg; Bernd Stegmayr; Rune Dahlqvist 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 91 KB

Pharmacokinetics of tinidazole in chroni

Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

✍ BL Flouvat; C Imbert; DM Dubois; BP Temperville; AF Roux; GC Chevalier; G Humber 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 752 KB

Oral pharmacokinetics of pirenzepine in

Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis

✍ T. MacGregor; K. Matzek; J. Keirns; M. Vinocur; A. Chonko 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 215 KB

The pharmacokinetic properties of pirenzepine following administration of a single, 50 mg oral dose were evaluated in three groups of subjects: group I, end stage renal disease requiring maintenance haemodialysis (CLCR 0 to 10 ml.min-1); group II, moderate renal insufficiency (CLCR 10 to 30 ml.min-1